Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Esperion Therapeutics Inc.

Analysts fell to the sidelines weighing in on Passage Bio (PASG) and Esperion (ESPR) with neutral ratings, indicating that the experts are neither ...

Analysts’ Top Healthcare Picks: Passage Bio (PASG), Esperion (ESPR)

Esperion Therapeutics (ESPR) has disclosed a new risk, in the Regulation category. The discussion emphasizes that Esperion Therapeutics’ Form 10-Q ...

Esperion Therapeutics’ 10-Q Forward-Looking Statements Highlight Significant Uncertainty and Investor Risk

Analysts are intrested in these 5 stocks: ( ($EXE) ), ( ($IP) ), ( ($ESPR) ), ( ($CMPS) ) and ( ($TNXP) ). Here is a breakdown of their recent


EXE, IP, ESPR, CMPS, TNXP Trending With Analysts

Esperion received a Hold rating and price target from Needham analyst Serge Belanger today. According to TipRanks, Belanger is a 5-star analyst wit...

Esperion (ESPR) was downgraded to a Hold Rating at Needham

Analysts are intrested in these 5 stocks: ( ($ESPR) ). Here is a breakdown of their recent ratings and the rationale behind them. Esperion Therapeu...

Esperion Stock Surges Onto Analysts’ Trending Radar

Esperion ( ($ESPR) ) just unveiled an announcement. On May 1, 2026, Esperion announced a definitive agreement under which funds managed by healthca...

Current Quarter	$-0.02	Next Quarter	$-0.02
Current Year	$0.05	Next Year	$0.22
QoQ Growth	+0.0%	YoY Growth	+340.0%
3Y EPS CAGR	+68.5%	Target Price	$2.91
Consensus	Buy	Upside	-6.7%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ESPR	$3.12	-0.32%	6.79M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ESPR	$3.12	-0.3%	6.79M
3
4
5
6

ESPR

ESPR

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Esperion Therapeutics Inc. Data in Excel

Get Esperion Therapeutics Inc. Data in Excel